EF
KRYS icon

Empowered Funds’s Krystal Biotech KRYS Stock Holding History

Empowered Funds’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
2,325
+49
+2% +$14.6K ﹤0.01% 1497
2026
Q1 		$588K Buy
+2,276
New +$606K ﹤0.01% 1585
2025
Q2 		– Sell
-1,211
Closed -$218K – 1803
2025
Q1 		$218K Buy
+1,211
New +$204K ﹤0.01% 1488
2023
Q4 		– Sell
-24,611
Closed -$2.85M – 1293
2023
Q3 		$2.85M Buy
24,611
+510
+2% +$62.2K 0.08% 328
2023
Q2 		$2.83M Buy
+24,101
New +$2.46M 0.1% 293

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Empowered Funds's KRYS Position: Q2 2026 in Review

Empowered Funds increased its Krystal Biotech (KRYS) stake by 2.2% in Q2 2026, buying an estimated $14.6K and bringing the position to 2,325 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Empowered Funds first reported a position in KRYS in Q2 2023 and has held it in 5 quarters since. The position peaked at $2.85M in Q3 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Empowered Funds held 2,325 shares of Krystal Biotech worth $864K as of Q2 2026.
  • Empowered Funds bought 49 Krystal Biotech shares in Q2 2026, an estimated $14.6K.
  • Krystal Biotech made up ﹤0.01% of Empowered Funds's portfolio in Q2 2026, its #1497 holding.
  • Empowered Funds first reported a position in Krystal Biotech in Q2 2023 and has held it in 5 quarters since.
  • Empowered Funds's Krystal Biotech position peaked at $2.85M in Q3 2023.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.